


Supplemental Figures for:
 Phase II Trial of Neoadjuvant Carboplatin and Nab-Paclitaxel in Patients with Triple Negative Breast Cancer
 Yuan Yuan et al.

Supplemental Figure 1. Diagram of patient distribution. Numbers of patient with pathology responses (black), mRNA array (green), and genetic or germline mutation testing (blue) are shown. pCR, pathological complete response; pts, patients

Yuan Supplemental Figure 1: Top



Supplemental Figure 2. Pathological response and DRD mutations (N=66*). Size of bar graph depicts the pathological response among patients with the numbers of patients within each RCB class and DRD group. WT, wild type; pCR, pathological complete response; RCB, residual cancer burden. *One patient progressed and did not receive surgery (no RCB status represented in this graph). Unknown, patient not eligible for genetic testing per NCCN guideline.

Yuan Supplemental Figure 2: Top

